<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04874662</url>
  </required_header>
  <id_info>
    <org_study_id>20.07.CLI</org_study_id>
    <nct_id>NCT04874662</nct_id>
  </id_info>
  <brief_title>Nicotinamide (NAM) and Pyridoxine (Vitamin B6) on Muscle Regeneration (&quot;Satellite-01 Study&quot;).</brief_title>
  <official_title>Efficacy and Safety of a Mix of Nicotinamide (NAM) and Pyridoxine (Vitamin B6) on Muscle Regeneration: a Randomized, Double-blind, Placebo-controlled Study (&quot;Satellite-01 Study&quot;).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of safety and efficacy of NAM/B6 oral administration on the amplification and&#xD;
      commitment of satellite cells after a muscle injury&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NAM/B6 oral administration after a muscle injury (&quot;Satellite-01 study&quot;): Effect on satellite&#xD;
      cells as measured by immunofluorescence (Pax7 and myogenin antibodies to detect amplifying&#xD;
      and committed satellite cells, respectively) on sections of muscle biopsies from the&#xD;
      stimulated leg (leg 2) by muscle biopsies, comparing the study intervention (NAM/B6) to the&#xD;
      control intervention (placebo)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2021</start_date>
  <completion_date type="Anticipated">July 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, double-blind, placebo-controlled, parallel group study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>immunofluorescence measurement</measure>
    <time_frame>9 days</time_frame>
    <description>Number of satellite cells as measured by immunofluorescence (Pax7 and myogenin antibodies to detect amplifying and committed satellite cells, respectively) on sections of muscle biopsies from the stimulated leg (leg 2) at day 4 and day 8 (muscle biopsies: MB3 and MB5), comparing the study intervention (NAM/B6) to the control intervention (placebo)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Muscle Injury</condition>
  <arm_group>
    <arm_group_label>Investigational NAM/B6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 VCaps® capsules daily (commercial vegetarian capsules made of Hydroxy Propyl Methyl Cellulose, a polymer of cellulose)&#xD;
Dosage per capsule: 357mg of nicotinamide, 9.5mg of pyridoxine and 195mg of microcrystalline cellulose&#xD;
Form:The VCaps® Size 00 will be used. They have a volume of 0.95 ml for 23.3 mm length and a diameter of 8.51 mm head / 8.16 mm body.daily of NAM/B6&#xD;
Frequency and duration: 2 capsules daily for 9 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules daily of microcrystalline cellulose excipient (337mg per capsule)&#xD;
Frequency and duration: 2 capsules daily for 9 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>NAM/B6</intervention_name>
    <description>Single daily dose administration will take place from Day 0 (V1) to Day 8 (V4) around 8 am after an overnight fast from the subsequent evening at 9 pm.</description>
    <arm_group_label>Investigational NAM/B6</arm_group_label>
    <arm_group_label>Placebo control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males aged ≥18 ≤ 50 years;&#xD;
&#xD;
          2. Subjects must be in good general health, as determined by the investigator or&#xD;
             delegate, based on a comprehensive medical evaluation at screening including detailed&#xD;
             medical history, full physical examination, blood pressure and heart rate&#xD;
             measurements, 12-lead electrocardiogram (ECG) and clinical laboratory tests;&#xD;
&#xD;
          3. Body mass index (BMI) between18.5 and 24.9 kg/m2;&#xD;
&#xD;
          4. Normal dietary habits;&#xD;
&#xD;
          5. Willing to adhere to the prohibitions and restrictions specified in the protocol;&#xD;
&#xD;
          6. Must understand the nature of the study and be capable of giving written informed&#xD;
             consent and be willing to report for the scheduled study visits and communicate to&#xD;
             study personnel about adverse events and concomitant medication use.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects presenting with the following blood pressure (BP) and heart rate (HR) values&#xD;
             at the screening visit after 10 minutes in supine position:&#xD;
&#xD;
               1. 95 mmHg ≤ systolic blood pressure (SBP) ≤ 140 mmHg,&#xD;
&#xD;
               2. 50 mmHg ≤ diastolic blood pressure (DBP) ≤ 95 mmHg,&#xD;
&#xD;
               3. 50 bpm &lt; HR &lt; 80 bpm,&#xD;
&#xD;
               4. Or any other out of expected range values considered clinically significant by&#xD;
                  the investigator;&#xD;
&#xD;
          2. Screening visit 12-lead ECG values which are:&#xD;
&#xD;
               1. 120 &lt; PR segment &lt; 220 ms,&#xD;
&#xD;
               2. QRS complex &lt; 120 ms,&#xD;
&#xD;
               3. QTcf &lt; 430 ms,&#xD;
&#xD;
               4. Sign of any trouble of sinusal automatism,&#xD;
&#xD;
               5. Or any other ECG finding considered clinically significant by the investigator;&#xD;
&#xD;
          3. Have any clinically significant abnormalities in serum chemistry, hematology, or&#xD;
             urinalysis at screening as judged by the investigator or delegate;&#xD;
&#xD;
          4. Active smokers;&#xD;
&#xD;
          5. Vegetarians or vegans;&#xD;
&#xD;
          6. Performed structured exercises within 3 months prior to participation in the study;&#xD;
&#xD;
          7. History or current use of anabolic steroids and/or growth hormone;&#xD;
&#xD;
          8. Use of corticosteroids within 3 months prior to participation in the study;&#xD;
&#xD;
          9. Current use of anticoagulant or anti-aggreging agents;&#xD;
&#xD;
         10. History or current use since 2 weeks before inclusion of any of the prohibited&#xD;
             medications as detailed in Section 6.6.2;&#xD;
&#xD;
         11. History or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal,&#xD;
             metabolic, hematological, neurologic, musculoskeletal, psychiatric, systemic or&#xD;
             infectious disease;&#xD;
&#xD;
         12. History or current use of drugs or alcohol (alcohol consumption &gt; 40 grams/day);&#xD;
&#xD;
         13. Known intolerance to foods containing the ingredients under investigation;&#xD;
&#xD;
         14. Knee pain that prevents application of the electrical muscle stimulation protocol;&#xD;
&#xD;
         15. Subjects who, in the judgment of the investigator, are likely to be non-compliant or&#xD;
             uncooperative during the study, or unable to cooperate because of a language problem,&#xD;
             poor mental development;&#xD;
&#xD;
         16. Subjects under administrative or legal supervision;&#xD;
&#xD;
         17. Have participated in a clinical study in the last 3 months and received compensation&#xD;
             beyond a certain approved and predefined limit.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kjaer, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Sports Medicine, Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elham Pazirandeh Micol</last_name>
    <phone>+ 41 76 674 1360</phone>
    <email>elham.pazirandehmicol@nestle.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bisepjerg-Frederiksbjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kjær</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

